Fanconi syndrome: Difference between revisions
Ostermayer (talk | contribs) (Created page with "Fanconi syndrome is a generalized dysfunction of the '''proximal renal tubule''' resulting in impaired reabsorption of glucose, amino acids, phosphate, bicarbonate, uric acid, potassium, sodium, and low-molecular-weight proteins. It produces a '''type 2 (proximal) renal tubular acidosis''' and may cause life-threatening hypokalemia, metabolic acidosis, dehydration, and bone disease.<ref name="StatPearls">F...") |
(Moved intro paragraph into Background as bullets; removed excessive bold from bullet lead-ins; added Renal tubular disorders, Hypokalemia, and Acid-base disorders DDX templates; bold retained for critical items only) |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Fanconi syndrome is a generalized dysfunction of the proximal renal tubule resulting in impaired reabsorption of glucose, amino acids, phosphate, bicarbonate, uric acid, potassium, sodium, and low-molecular-weight proteins. | |||
*It produces a type 2 (proximal) [[Renal tubular acidosis|renal tubular acidosis]] and may cause life-threatening [[Hypokalemia|hypokalemia]], [[Metabolic acidosis|metabolic acidosis]], dehydration, and bone disease.<ref name="StatPearls">Fanconi Syndrome. ''StatPearls''. 2025. PMID: 30521243</ref> It is not the same as [[Fanconi anemia]], which is a separate inherited bone marrow failure syndrome. | |||
*The proximal convoluted tubule (PCT) normally reabsorbs ~65% of filtered sodium, water, bicarbonate, glucose, amino acids, phosphate, and uric acid | *The proximal convoluted tubule (PCT) normally reabsorbs ~65% of filtered sodium, water, bicarbonate, glucose, amino acids, phosphate, and uric acid | ||
*In Fanconi syndrome, '''global PCT dysfunction''' causes urinary wasting of all these solutes simultaneously<ref name="StatPearls"/> | *In Fanconi syndrome, '''global PCT dysfunction''' causes urinary wasting of all these solutes simultaneously<ref name="StatPearls"/> | ||
| Line 8: | Line 8: | ||
===Inherited causes=== | ===Inherited causes=== | ||
* | * [[Cystinosis]] — most common inherited cause (presents in infancy, 6-18 months) | ||
*[[Wilson disease]] | *[[Wilson disease]] | ||
*Hereditary fructose intolerance | *Hereditary fructose intolerance | ||
| Line 20: | Line 20: | ||
===Acquired causes (most EM-relevant)=== | ===Acquired causes (most EM-relevant)=== | ||
* | * Medications (most common acquired cause):<ref name="StatPearls"/><ref name="Medscape">Fanconi Syndrome. ''Medscape''. 2024.</ref> | ||
** | ** Tenofovir (TDF; especially in HIV patients with pre-existing renal impairment) — most commonly encountered drug cause today | ||
** | ** Ifosfamide — particularly in children after cumulative doses | ||
** | ** Cisplatin, carboplatin | ||
** | ** Valproic acid — especially with polytherapy and prolonged use | ||
** | ** Expired tetracyclines (degradation products are directly nephrotoxic) | ||
**Adefovir, cidofovir, didanosine | **Adefovir, cidofovir, didanosine | ||
**Aminoglycosides (gentamicin) | **Aminoglycosides (gentamicin) | ||
**Lenalidomide, streptozocin | **Lenalidomide, streptozocin | ||
* | * Heavy metals: | ||
**[[Lead poisoning]] (most common heavy metal cause in children) | **[[Lead poisoning]] (most common heavy metal cause in children) | ||
**Cadmium, mercury, platinum, uranium | **Cadmium, mercury, platinum, uranium | ||
* | * Paraproteinemia: | ||
**[[Multiple myeloma]] (light chain proximal tubulopathy) | **[[Multiple myeloma]] (light chain proximal tubulopathy) | ||
**AL amyloidosis | **AL amyloidosis | ||
* | * Other: | ||
**Renal transplant | **Renal transplant | ||
**Toluene exposure (glue sniffing) | **Toluene exposure (glue sniffing) | ||
| Line 46: | Line 46: | ||
===Acute/ED presentation=== | ===Acute/ED presentation=== | ||
* | * [[Hypokalemia]] — may be '''severe and life-threatening'''; case reports of [[Cardiac arrest|cardiac arrest]] from Fanconi-related hypokalemia<ref name="Cardiac">A 57-Year-Old Female Presenting With Cardiopulmonary Arrest Secondary to Severe Hypokalemia From a Fanconi-Like Syndrome. ''Cureus''. 2024;16(3):e55705. doi:10.7759/cureus.55705</ref> | ||
* | * [[Metabolic acidosis]] — non-anion gap (hyperchloremic) from '''proximal (type 2) [[Renal tubular acidosis|RTA]]''' (bicarbonate wasting) | ||
* | * Polyuria, polydipsia (from impaired water/sodium reabsorption) | ||
* | * Dehydration, volume depletion | ||
* | * Muscle weakness (from hypokalemia and hypophosphatemia) | ||
*Nausea, vomiting | *Nausea, vomiting | ||
*Fatigue, malaise | *Fatigue, malaise | ||
===Chronic/subacute presentation=== | ===Chronic/subacute presentation=== | ||
* | * Children: | ||
**Failure to thrive, growth retardation | **Failure to thrive, growth retardation | ||
** | ** Rickets (hypophosphatemic; from phosphate wasting + impaired 1,25-dihydroxyvitamin D synthesis in PCT) | ||
**Bone pain, pathologic fractures | **Bone pain, pathologic fractures | ||
**Polyuria, polydipsia | **Polyuria, polydipsia | ||
* | * Adults: | ||
** | ** Osteomalacia (bone pain, pathologic fractures, proximal muscle weakness) | ||
**Chronic fatigue, muscle weakness | **Chronic fatigue, muscle weakness | ||
**Kidney stones (hypercalciuria in some forms) | **Kidney stones (hypercalciuria in some forms) | ||
**Progressive chronic kidney disease | **Progressive chronic kidney disease | ||
* | * Cystinosis-specific: corneal cystine crystals, hepatomegaly, hypothyroidism, retinal depigmentation, growth failure | ||
===Key laboratory pattern ("the Fanconi fingerprint")=== | ===Key laboratory pattern ("the Fanconi fingerprint")=== | ||
* | * Glycosuria with NORMAL serum glucose (not diabetes — inappropriately low renal glucose threshold) | ||
* | * Generalized aminoaciduria | ||
* | * Phosphaturia with hypophosphatemia | ||
* | * Bicarbonaturia with non-anion gap metabolic acidosis (proximal RTA) | ||
* | * Hypokalemia (renal potassium wasting) | ||
* | * Hypouricemia (uric acid wasting) | ||
* | * Low-molecular-weight proteinuria (β₂-microglobulin, retinol-binding protein) | ||
==Differential diagnosis== | ==Differential diagnosis== | ||
| Line 97: | Line 97: | ||
*Renal glycosuria (isolated SGLT2 mutation) | *Renal glycosuria (isolated SGLT2 mutation) | ||
*Pregnancy | *Pregnancy | ||
{{Renal tubular disorders DDX}} | |||
{{Hypokalemia DDX}} | |||
{{Acid-base disorders DDX}} | |||
==Evaluation== | ==Evaluation== | ||
===Workup=== | ===Workup=== | ||
* | * BMP: hypokalemia, hypophosphatemia, low bicarbonate (non-anion gap metabolic acidosis), low uric acid; BUN/creatinine for renal function | ||
* | * ABG/VBG: non-anion gap metabolic acidosis (hyperchloremic); urine pH may be <5.5 (unlike distal RTA) if serum bicarbonate is below the reabsorptive threshold | ||
* | * Urinalysis: | ||
** | ** Glucosuria (with normal serum glucose — the hallmark clue) | ||
**Proteinuria (low-molecular-weight) | **Proteinuria (low-molecular-weight) | ||
* | * Urine electrolytes: elevated urine potassium (transtubular potassium gradient >7 suggests renal K⁺ wasting) | ||
* | * Urine amino acids: generalized aminoaciduria (elevated excretion of virtually all amino acids) | ||
* | * Fractional excretion of phosphate (FePO₄): elevated (>5%) | ||
* | * Fractional excretion of uric acid: elevated (>10%) | ||
* | * Serum phosphate, uric acid, calcium, magnesium, vitamin D (25-OH and 1,25-OH), PTH | ||
* | * Urine β₂-microglobulin — marker of proximal tubular injury<ref name="StatPearls"/> | ||
* | * ECG: assess for hypokalemia-related changes (U waves, flattened T waves, ST depression, prolonged QT, arrhythmias) | ||
* | * Additional workup directed at underlying cause: | ||
**Medication review (tenofovir, valproic acid, ifosfamide, expired tetracyclines) | **Medication review (tenofovir, valproic acid, ifosfamide, expired tetracyclines) | ||
**Serum and urine protein electrophoresis, free light chains (multiple myeloma) | **Serum and urine protein electrophoresis, free light chains (multiple myeloma) | ||
| Line 127: | Line 132: | ||
==Management== | ==Management== | ||
===Emergency management (acute presentations)=== | ===Emergency management (acute presentations)=== | ||
* | * Hypokalemia: | ||
**Aggressive IV and PO potassium repletion; may be '''profoundly refractory''' due to ongoing renal losses<ref name="Cardiac"/> | **Aggressive IV and PO potassium repletion; may be '''profoundly refractory''' due to ongoing renal losses<ref name="Cardiac"/> | ||
**Continuous cardiac monitoring if K⁺ <3.0 mEq/L or symptomatic | **Continuous cardiac monitoring if K⁺ <3.0 mEq/L or symptomatic | ||
**Target serum K⁺ >4.0 mEq/L | **Target serum K⁺ >4.0 mEq/L | ||
**Consider '''amiloride''' or '''spironolactone''' to reduce renal potassium wasting | **Consider '''amiloride''' or '''spironolactone''' to reduce renal potassium wasting | ||
* | * Metabolic acidosis: | ||
**Oral or IV '''sodium bicarbonate''' or '''sodium citrate/potassium citrate''' (Bicitra, Polycitra) | **Oral or IV '''sodium bicarbonate''' or '''sodium citrate/potassium citrate''' (Bicitra, Polycitra) | ||
**Large doses may be required (10-15 mEq/kg/day in children) because bicarbonate is lost in the urine | **Large doses may be required (10-15 mEq/kg/day in children) because bicarbonate is lost in the urine | ||
**Caution: bicarbonate repletion may worsen hypokalemia (drives K⁺ intracellularly and increases distal delivery); replete potassium FIRST or concurrently | **Caution: bicarbonate repletion may worsen hypokalemia (drives K⁺ intracellularly and increases distal delivery); replete potassium FIRST or concurrently | ||
* | * Dehydration: IV fluid resuscitation; may need large volumes due to polyuria | ||
* | * Hypophosphatemia: | ||
**Oral phosphate supplementation (Neutra-Phos, K-Phos) | **Oral phosphate supplementation (Neutra-Phos, K-Phos) | ||
**IV phosphate if severe (<1 mg/dL) or symptomatic | **IV phosphate if severe (<1 mg/dL) or symptomatic | ||
* | * Hypoglycemia: IV dextrose if present (hereditary fructose intolerance may present with hypoglycemia) | ||
===Identify and treat the underlying cause=== | ===Identify and treat the underlying cause=== | ||
* | * Drug-induced: '''discontinue the offending agent''' — this is the most important intervention for acquired Fanconi syndrome<ref name="StatPearls"/> | ||
**Tenofovir: switch to tenofovir alafenamide (TAF) or alternative antiretroviral | **Tenofovir: switch to tenofovir alafenamide (TAF) or alternative antiretroviral | ||
**Valproic acid: consider alternative antiepileptic | **Valproic acid: consider alternative antiepileptic | ||
**Expired tetracyclines: discard | **Expired tetracyclines: discard | ||
**Recovery after drug withdrawal may take '''weeks to months'''<ref name="Medscape"/> | **Recovery after drug withdrawal may take '''weeks to months'''<ref name="Medscape"/> | ||
* | * Heavy metal poisoning: chelation therapy as appropriate (see [[Lead poisoning]]) | ||
* | * Multiple myeloma/paraproteinemia: hematology/oncology referral for treatment of underlying disease | ||
* | * Cystinosis: '''cysteamine''' (Cystagon) — reduces intracellular cystine accumulation; early initiation improves renal outcomes | ||
===Long-term supplementation=== | ===Long-term supplementation=== | ||
* | * Bicarbonate/citrate: oral sodium bicarbonate or potassium citrate for chronic metabolic acidosis | ||
* | * Phosphate: oral phosphate supplements | ||
* | * Vitamin D: calcitriol (1,25-dihydroxyvitamin D) — PCT dysfunction impairs conversion of 25-OH to active form | ||
* | * Potassium: oral supplementation; potassium-sparing diuretics if refractory | ||
*Nephrology follow-up for ongoing management and monitoring of renal function | *Nephrology follow-up for ongoing management and monitoring of renal function | ||
==Disposition== | ==Disposition== | ||
* | * Severe hypokalemia (K⁺ <2.5 mEq/L), symptomatic hypokalemia, or cardiac arrhythmias: admit to monitored setting; continuous telemetry; serial electrolytes<ref name="Cardiac"/> | ||
* | * Severe metabolic acidosis (pH <7.2): admit for IV bicarbonate and electrolyte management | ||
* | * Significant dehydration or hemodynamic instability: admit for IV resuscitation | ||
* | * New diagnosis of Fanconi syndrome: may require admission or urgent outpatient workup depending on severity; nephrology consultation | ||
* | * Stable, known Fanconi syndrome with mild electrolyte abnormalities: outpatient management with close nephrology follow-up, medication adjustment, and return precautions for weakness, palpitations, or syncope | ||
* | * Medication-induced Fanconi: ensure offending drug is held and arrange nephrology and primary care follow-up for drug substitution and monitoring of recovery | ||
==See Also== | ==See Also== | ||
Revision as of 14:27, 19 March 2026
Background
- Fanconi syndrome is a generalized dysfunction of the proximal renal tubule resulting in impaired reabsorption of glucose, amino acids, phosphate, bicarbonate, uric acid, potassium, sodium, and low-molecular-weight proteins.
- It produces a type 2 (proximal) renal tubular acidosis and may cause life-threatening hypokalemia, metabolic acidosis, dehydration, and bone disease.[1] It is not the same as Fanconi anemia, which is a separate inherited bone marrow failure syndrome.
- The proximal convoluted tubule (PCT) normally reabsorbs ~65% of filtered sodium, water, bicarbonate, glucose, amino acids, phosphate, and uric acid
- In Fanconi syndrome, global PCT dysfunction causes urinary wasting of all these solutes simultaneously[1]
- Pathophysiology centers on mitochondrial dysfunction → ATP depletion → failure of Na⁺/K⁺-ATPase and energy-dependent transport systems[1]
- Can be inherited or acquired; acquired forms are more relevant to the emergency physician
Inherited causes
- Cystinosis — most common inherited cause (presents in infancy, 6-18 months)
- Wilson disease
- Hereditary fructose intolerance
- Galactosemia
- Glycogen storage diseases
- Lowe syndrome (oculocerebrorenal syndrome)
- Dent disease
- Fanconi-Bickel syndrome
- Tyrosinemia type 1
- Mitochondrial cytopathies
Acquired causes (most EM-relevant)
- Medications (most common acquired cause):[1][2]
- Tenofovir (TDF; especially in HIV patients with pre-existing renal impairment) — most commonly encountered drug cause today
- Ifosfamide — particularly in children after cumulative doses
- Cisplatin, carboplatin
- Valproic acid — especially with polytherapy and prolonged use
- Expired tetracyclines (degradation products are directly nephrotoxic)
- Adefovir, cidofovir, didanosine
- Aminoglycosides (gentamicin)
- Lenalidomide, streptozocin
- Heavy metals:
- Lead poisoning (most common heavy metal cause in children)
- Cadmium, mercury, platinum, uranium
- Paraproteinemia:
- Multiple myeloma (light chain proximal tubulopathy)
- AL amyloidosis
- Other:
- Renal transplant
- Toluene exposure (glue sniffing)
- Aristolochic acid (herbal medicines)
- Paraquat poisoning
Clinical features
- Presentation varies widely depending on the underlying cause, severity, and chronicity
- May range from an incidental laboratory finding to life-threatening electrolyte emergency
Acute/ED presentation
- Hypokalemia — may be severe and life-threatening; case reports of cardiac arrest from Fanconi-related hypokalemia[3]
- Metabolic acidosis — non-anion gap (hyperchloremic) from proximal (type 2) RTA (bicarbonate wasting)
- Polyuria, polydipsia (from impaired water/sodium reabsorption)
- Dehydration, volume depletion
- Muscle weakness (from hypokalemia and hypophosphatemia)
- Nausea, vomiting
- Fatigue, malaise
Chronic/subacute presentation
- Children:
- Failure to thrive, growth retardation
- Rickets (hypophosphatemic; from phosphate wasting + impaired 1,25-dihydroxyvitamin D synthesis in PCT)
- Bone pain, pathologic fractures
- Polyuria, polydipsia
- Adults:
- Osteomalacia (bone pain, pathologic fractures, proximal muscle weakness)
- Chronic fatigue, muscle weakness
- Kidney stones (hypercalciuria in some forms)
- Progressive chronic kidney disease
- Cystinosis-specific: corneal cystine crystals, hepatomegaly, hypothyroidism, retinal depigmentation, growth failure
Key laboratory pattern ("the Fanconi fingerprint")
- Glycosuria with NORMAL serum glucose (not diabetes — inappropriately low renal glucose threshold)
- Generalized aminoaciduria
- Phosphaturia with hypophosphatemia
- Bicarbonaturia with non-anion gap metabolic acidosis (proximal RTA)
- Hypokalemia (renal potassium wasting)
- Hypouricemia (uric acid wasting)
- Low-molecular-weight proteinuria (β₂-microglobulin, retinol-binding protein)
Differential diagnosis
Proximal Renal tubular acidosis
- Isolated proximal RTA (type 2) without full Fanconi features
- Renal tubular acidosis (type 1)
- Type 4 RTA (hypoaldosteronism)
Other causes of non-anion gap metabolic acidosis
- Diarrhea
- Ureteral diversion
- Carbonic anhydrase inhibitors (acetazolamide)
Other causes of unexplained hypokalemia
- Diuretic use
- Hyperaldosteronism
- Bartter syndrome, Gitelman syndrome
- Vomiting, GI losses
- Licorice ingestion
Other causes of glycosuria with normal glucose
- Renal glycosuria (isolated SGLT2 mutation)
- Pregnancy
Renal tubular disorders
- Salt-wasting tubulopathies
- Gitelman syndrome — distal convoluted tubule (NCC defect); hypokalemia, hypomagnesemia, hypocalciuria, metabolic alkalosis
- Bartter syndrome — thick ascending limb (NKCC2/ROMK/ClC-Kb defect); hypokalemia, hypercalciuria, metabolic alkalosis
- Liddle syndrome — collecting duct (ENaC gain-of-function); hypokalemia, hypertension, metabolic alkalosis
- Renal tubular acidosis
- Renal tubular acidosis type I (distal) — hypokalemia, metabolic acidosis, nephrocalcinosis
- Renal tubular acidosis type II (proximal) — hypokalemia, metabolic acidosis, Fanconi syndrome
- Renal tubular acidosis type IV — hyperkalemia, metabolic acidosis, hypoaldosteronism
- Inherited disorders of tubular transport
- Cystinuria — proximal tubule amino acid transport defect; recurrent cystine stones
- Fanconi syndrome — proximal tubule generalized dysfunction; glucosuria, aminoaciduria, phosphaturia
- Nephrogenic diabetes insipidus — collecting duct (aquaporin/V2R defect); polyuria, hypernatremia
- Dent disease — proximal tubule (ClC-5 defect); low molecular weight proteinuria, nephrocalcinosis
- Acquired tubulopathies
- Diuretic use/abuse (thiazide mimics Gitelman; loop mimics Bartter)
- Aminoglycosides nephrotoxicity
- Cisplatin nephrotoxicity
- Amphotericin B nephrotoxicity
- Lithium-induced nephrogenic DI
Hypokalemia
- Decreased intake
- Poor dietary intake
- Anorexia
- Transcellular shift (redistribution)
- Metabolic alkalosis
- Insulin administration
- Beta-agonists (albuterol)
- Theophylline toxicity
- Hypokalemic periodic paralysis
- Thyrotoxic periodic paralysis
- Renal losses
- Diuretics (thiazide, loop)
- Hyperaldosteronism
- Cushing syndrome
- Renal tubular acidosis (type I, II)
- Gitelman syndrome
- Bartter syndrome
- Liddle syndrome
- Diabetic ketoacidosis (osmotic diuresis)
- Magnesium depletion
- GI losses
- Vomiting
- Diarrhea
- Nasogastric suction
- Laxative abuse
- Villous adenoma
- Other
- Hypothermia
- Dialysis
Acid-base disorders
Evaluation
Workup
- BMP: hypokalemia, hypophosphatemia, low bicarbonate (non-anion gap metabolic acidosis), low uric acid; BUN/creatinine for renal function
- ABG/VBG: non-anion gap metabolic acidosis (hyperchloremic); urine pH may be <5.5 (unlike distal RTA) if serum bicarbonate is below the reabsorptive threshold
- Urinalysis:
- Glucosuria (with normal serum glucose — the hallmark clue)
- Proteinuria (low-molecular-weight)
- Urine electrolytes: elevated urine potassium (transtubular potassium gradient >7 suggests renal K⁺ wasting)
- Urine amino acids: generalized aminoaciduria (elevated excretion of virtually all amino acids)
- Fractional excretion of phosphate (FePO₄): elevated (>5%)
- Fractional excretion of uric acid: elevated (>10%)
- Serum phosphate, uric acid, calcium, magnesium, vitamin D (25-OH and 1,25-OH), PTH
- Urine β₂-microglobulin — marker of proximal tubular injury[1]
- ECG: assess for hypokalemia-related changes (U waves, flattened T waves, ST depression, prolonged QT, arrhythmias)
- Additional workup directed at underlying cause:
- Medication review (tenofovir, valproic acid, ifosfamide, expired tetracyclines)
- Serum and urine protein electrophoresis, free light chains (multiple myeloma)
- Serum copper, ceruloplasmin (Wilson disease)
- Lead level
- White blood cell cystine level (cystinosis)
- Slit-lamp examination (cystine corneal crystals)
Diagnosis
- Clinical diagnosis based on the constellation of: glycosuria with normoglycemia + generalized aminoaciduria + phosphaturia + bicarbonaturia + hypokalemia[4]
- No single test is diagnostic; the pattern of proximal tubular losses is key
- Once Fanconi syndrome is identified, the underlying cause must be sought
Management
Emergency management (acute presentations)
- Hypokalemia:
- Aggressive IV and PO potassium repletion; may be profoundly refractory due to ongoing renal losses[3]
- Continuous cardiac monitoring if K⁺ <3.0 mEq/L or symptomatic
- Target serum K⁺ >4.0 mEq/L
- Consider amiloride or spironolactone to reduce renal potassium wasting
- Metabolic acidosis:
- Oral or IV sodium bicarbonate or sodium citrate/potassium citrate (Bicitra, Polycitra)
- Large doses may be required (10-15 mEq/kg/day in children) because bicarbonate is lost in the urine
- Caution: bicarbonate repletion may worsen hypokalemia (drives K⁺ intracellularly and increases distal delivery); replete potassium FIRST or concurrently
- Dehydration: IV fluid resuscitation; may need large volumes due to polyuria
- Hypophosphatemia:
- Oral phosphate supplementation (Neutra-Phos, K-Phos)
- IV phosphate if severe (<1 mg/dL) or symptomatic
- Hypoglycemia: IV dextrose if present (hereditary fructose intolerance may present with hypoglycemia)
Identify and treat the underlying cause
- Drug-induced: discontinue the offending agent — this is the most important intervention for acquired Fanconi syndrome[1]
- Tenofovir: switch to tenofovir alafenamide (TAF) or alternative antiretroviral
- Valproic acid: consider alternative antiepileptic
- Expired tetracyclines: discard
- Recovery after drug withdrawal may take weeks to months[2]
- Heavy metal poisoning: chelation therapy as appropriate (see Lead poisoning)
- Multiple myeloma/paraproteinemia: hematology/oncology referral for treatment of underlying disease
- Cystinosis: cysteamine (Cystagon) — reduces intracellular cystine accumulation; early initiation improves renal outcomes
Long-term supplementation
- Bicarbonate/citrate: oral sodium bicarbonate or potassium citrate for chronic metabolic acidosis
- Phosphate: oral phosphate supplements
- Vitamin D: calcitriol (1,25-dihydroxyvitamin D) — PCT dysfunction impairs conversion of 25-OH to active form
- Potassium: oral supplementation; potassium-sparing diuretics if refractory
- Nephrology follow-up for ongoing management and monitoring of renal function
Disposition
- Severe hypokalemia (K⁺ <2.5 mEq/L), symptomatic hypokalemia, or cardiac arrhythmias: admit to monitored setting; continuous telemetry; serial electrolytes[3]
- Severe metabolic acidosis (pH <7.2): admit for IV bicarbonate and electrolyte management
- Significant dehydration or hemodynamic instability: admit for IV resuscitation
- New diagnosis of Fanconi syndrome: may require admission or urgent outpatient workup depending on severity; nephrology consultation
- Stable, known Fanconi syndrome with mild electrolyte abnormalities: outpatient management with close nephrology follow-up, medication adjustment, and return precautions for weakness, palpitations, or syncope
- Medication-induced Fanconi: ensure offending drug is held and arrange nephrology and primary care follow-up for drug substitution and monitoring of recovery
See Also
- Renal tubular acidosis
- Hypokalemia
- Hypophosphatemia
- Metabolic acidosis
- Multiple myeloma
- Wilson disease
- Lead poisoning
- Tenofovir
- Cystinosis
External Links
- StatPearls — Fanconi Syndrome
- Medscape — Fanconi Syndrome
- Merck Manual — Fanconi Syndrome
- Cureus — Cardiopulmonary Arrest Secondary to Severe Hypokalemia From Fanconi-Like Syndrome (2024)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Fanconi Syndrome. StatPearls. 2025. PMID: 30521243
- ↑ 2.0 2.1 Fanconi Syndrome. Medscape. 2024.
- ↑ 3.0 3.1 3.2 A 57-Year-Old Female Presenting With Cardiopulmonary Arrest Secondary to Severe Hypokalemia From a Fanconi-Like Syndrome. Cureus. 2024;16(3):e55705. doi:10.7759/cureus.55705
- ↑ Fanconi Syndrome. Merck Manual Professional Edition. 2024.
